leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience gets approval for CBD DehydraTECH hypertension study in Europe

The study will evaluate blood pressure reduction in 24 pre- or mild hypertension patients, who will receive a 300 milligram dose of CBD with or without DehydraTECH

Person holding test tube at golden hour
DehydraTECH works by improving the delivery of substances such as CBD, which is fat-soluble and thus poorly absorbed by the body when taken orally

Lexaria Bioscience Corp (CSE:LXX) (OTC:LXRP) has won approval from the ethics board of a European university research hospital to conduct an exploratory clinical study of CBD formulated with its DehydraTECH drug delivery technology as a treatment for hypertension patients.

The study will evaluate blood pressure reduction in 24 pre- or mild hypertension patients, who will receive a 300 milligram dose of CBD with or without DehydraTECH. The primary endpoints are blood pressure and heart rate.

The company expects to have the results of the study by November.

READ: Lexaria Bioscience files application with senior US stock exchange to request an uplisting of its common stock

"Lexaria believes that this study, if positive, will strengthen its value proposition pursuant to its intention to seek out pharmaceutical industry partnering opportunities with its DehydraTECH platform technology," CEO Chris Bunka said in a statement. "Positive results in this study are expected to be of particular interest to the antihypertensive products sector that is valued at over $22 billion."

Hypertension affects more than 1 billion people globally, the company said, but only 13% of those affected have the condition under control, according to the Centers for Disease Control and Prevention.

DehydraTECH works by improving the delivery of substances such as CBD, which is fat-soluble and thus poorly absorbed by the body when taken orally. 

The study is meant to compliment a 2018 study, which showed a 90mg dose of Lexaria's TurboCBD oral capsule formulation provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream and larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD, the company said. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 0.245 CAD

CSE:LXX
Market: CSE
Market Cap: $22.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

3 weeks, 1 day ago

2 min read